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Abstract  
BACKGROUND: Liver histology remains the gold standard for assessing non-alcoholic fatty liver 
disease (NAFLD). Noninvasive serological markers and radiological methods have been developed 
to evaluate steatosis to avoid biopsy.  
AIM: To put cutoff value for liver enzymes that could predict non-alcoholic steatohepatitis (NASH).  
PATIENTS AND METHODS: This study was conducted on 54 patients (with NAFLD diagnosed by 
the US). Patients were subjected to history, physical, anthropometric measurements, investigations 
including liver enzymes, abdominal US, and liver biopsy. According to biopsy results, patients were 
subdivided according to NASH development. Also, biopsy results were correlated to the levels of 
liver enzymes.  
RESULTS: Forty-seven patients who were suspected to have NAFLD by sonar were confirmed by 
biopsy. There was a significant correlation between steatosis degree in biopsy and sonar. 
Correlation study between steatosis in biopsy and ALT level showed highly significant positive 
correlation. Correlation study between steatosis in biopsy on one side & AST and GGT on the other 
side showed significant positive correlation. Cutoff value for detection of NASH using ALT & AST & 
and GGT were 50.5, 56, 60.5 respectively with sensitivity = 95.5, 90.5, 86.4 % and specificity = 
93.8, 100, 87.5%.  
CONCLUSION: Cut off values of liver enzymes can be combined with abdominal sonar to predict 
NASH. 
 
 
Introduction 
 
Non-alcoholic fatty liver disease (NAFLD) is 
one of the manifestations of metabolic syndrome, that 
include hypertension, diabetes, excess body fat 
around the waist or abnormal cholesterol levels that 
can predispose to heart disease, diabetes, and stroke 
[1]. 
The prevalence of NAFLD is very high in 
obese and overweight individuals. NAFLD spectrum 
ranges from simple fatty infiltration to more severe 
manifestations such as hepatocyte inflammation, 
hepatic fibrosis, and cirrhosis [2]. 
Liver biopsy is considered the best method for 
determining disease stage in NAFLD. A biopsy is not 
convenient for very large studies and especially for 
studying hepatic fibrosis progression as it is invasive. 
Moreover, histological assessment of NAFLD may 
cause sampling error and can result in 
misinterpretation of the fibrosis score especially in 
cases of insufficient specimen [3]. 
Ultrasound (US) is now the most widely used 
investigation for screening asymptomatic people with 
abnormal liver functions and suspected fatty liver [4]. 
Noninvasive serological markers may be used to 
assess steatosis and inflammation to avoid the need 
for biopsy [5]. In patients with NAFLD, serum 
Gamma-glutamyltransferase (GGT) is often raised 
and it has been linked to increased death rate [4]. 
Alanine aminotransferase (ALT) can be used as an 
indicator for liver injury. It is an important issue to 
differentiate simple steatosis from steatohepatitis 
because steatohepatitis has a progressive course and 
can cause liver failure [6]. 
The aim of this study was to evaluate liver 
enzymes and ultrasonic staging of hepatic steatosis 
as predictors for the severity of NAFLD, and trying to 
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put cutoff values for liver enzymes that could predict 
the development of non-alcoholic steatohepatitis 
(NASH). 
 
 
Patients and Methods 
 
This study was performed in Kasr El-Ainy 
hospital, Internal Medicine outpatient clinic over a 
period of 11 months on 54 obese subjects (BMI 
”body mass index” < 30 kg/m^2). They came 
complaining of dyspepsia, 17 patients (31.5 %), 
osteoarthritis, 15 patients (27.8 %), back pain, 12 
patients (22.2 %) and obesity, 10 patients (18.5 %). 
The selection of participants in this study was 
based on the following Inclusion criteria: 
1. All participants aged above 18 years. 
2. BMI above 30 kg/m^2. 
3. All patients showed a picture of bright liver 
± hepatomegaly on abdominal ultrasound.  
Exclusion criteria: 
1. Patients are known to be alcoholic. 
2. Patients are known to be positive for 
hepatitis C or B. 
3. Patients are known to be diabetic. 
Each patient was subjected to full medical 
history, full clinical examination, and anthropometric 
measurements (weight and height of each participant 
were measured while the participant was clothed only 
in a light gown, and the BMI was calculated as body 
weight in kilogram (kg) divided by height squared in 
meters “m” (Kg/m^2), also waist circumference `was 
measured midway between rib margin and the iliac 
crest in a standing position by the same examiner. 
Serum biochemistry profile (including serum 
levels of ALT, AST “aspartate transferase” and GGT) 
was done for every participant. 
Abdominal US was performed by the same 
operator using a Toshiba Apilo xv scanner equipped 
with a broadband 5.3 megahertz curved array probe 
to assess the presence of liver steatosis (bright liver). 
Liver biopsy was taken for all patients who were 
suspected to have NAFLD by the abdominal US. 
Liver biopsy was fixed in ten percent neutral 
buffered formalin then embedded in paraffin blocks. 
Five micrometre thick sections were cut and stained 
with hematoxylin and eosin and examined under light 
microscope for histopathological diagnosis and 
scoring using NAS “NAFLD activity score” scoring 
system according to Histological Scoring System for 
Nonalcoholic Fatty Liver Disease [7]. This scoring 
system addresses the full spectrum of lesions of 
NAFLD and allows a diagnostic categorization into 
NASH, borderline NASH or not NASH. Fibrosis 
staging was evaluated (separately from NASH) from 0 
to 4 scales [8].
 
As regarding statistical analysis, we 
considered borderline NASH and NASH as one group 
to facilitate comparison between the 2 studied groups 
(NASH and non-NASH). 
 
Ethics 
The study protocol conformed to ethical 
guidelines of the 1975 declaration of Helsinki, 
approved by Cairo University Research Ethics 
Committee (REC) (No.n-7-2015 in 28-5-2015). 
A written informed consent was obtained from 
all patients participating in the study. Data were 
statistically described in terms of mean  standard 
deviation ( SD), median and range, or frequencies 
(number of cases) and percentages when 
appropriate. Comparison of numerical variables 
between the study groups was done using Kruskal-
Wallis test with posthoc multiple 2-group 
comparisons. For comparing categorical data, Chi-
square (2) test was performed. The exact test was 
used instead when the expected frequency is less 
than 5. Agreement between ultrasound and biopsy 
results was tested using kappa statistic. P values 
less than 0.05 was considered statistically 
significant. All statistical calculations were done 
using computer programs SPSS (Statistical Package 
for the Social Science; SPSS Inc., Chicago, IL, USA) 
version 15 for Microsoft Windows. 
Receiver operator characteristic (ROC) 
curves were derived and area under the curve (AUC) 
analysis performed to get the best cutoff values for 
predicting NASH. 
 
 
Results 
 
The present study included 54 patients, 
suspected to have NAFLD (clinically & by 
abdominal ultrasound); and selected from the 
outpatient clinic. There were 50 females (92.6%) and 
4 males (7.4%). The age of the participants ranged 
from 18- 60 years with a mean ± SD = 43.17 ± 7.371. 
BMI of the participants ranged from 30.2kg/m ^2 to 
42.1 kg/m^2 with a mean ± SD = 34.774 ± 3.7613. 
Abdominal US showed a high sensitivity in detection 
of NAFLD as 87% of the patients who were 
suspected to have NAFLD by sonar were confirmed 
to have NAFLD by liver biopsy (47 patients out of 54 
patients). To facilitate statistical data, we considered 
fibrofatty and grade 1 steatosis in sonar as one group 
(group 1), also we considered grade 3 and 4 steatosis 
as one group (group 3). As to liver biopsy, we 
 Salman et al. Serum Liver Enzymes as A Prediction of Non-Alcoholic Fatty Liver Disease 
______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci.                                                                                                                                                                                                         3 
 
considered grade 0 and 1 steatosis as one group 
(group 1), then we correlate grading of steatosis by 
the abdominal US to grading of steatosis by liver 
biopsy.  
 
Figure 1: Correlation between ultrasonic staging of steatosis & 
steatosis in liver biopsy 
 
We found that there was a significant 
correlation between both parameters. The sensitivity 
of sonar in detecting steatosis grade compared to 
biopsy was: 61% in grade 1, 25% in grade 2, and 75% 
in grade 3 (Figure 1). 
 
Figure 2: Correlation between serum alanine transferase (ALT) & 
non-alcoholic steatohepatitis (NASH) score in liver biopsy 
 
Correlation study between steatosis in biopsy 
& other parameters revealed: 1-Highly significant 
positive correlation with ALT (Figure 2) (r = 0.8, P = 
0.0001); 2- Positive correlation with AST (r = 0.2, P 
=0.05); 3- Positive correlation with GGT (R = 0.4, P = 
0.05). 
 
Figure 3: ROC curve to detect a cut off value of serum ALT that 
could predict the development of NASH 
According to the results of the liver biopsy, 
patients were divided into 2 groups: Group 1included 
patients who have NASH (NASH and borderline 
NASH by biopsy). They were 34 patients out of the 54 
patients. Group 2 includes patients who do not have 
NASH. They were 20 patients out of the 54 patients. 
Comparison between NASH & non-NASH groups as 
regards laboratory data revealed the significantly 
higher level of ALT, AST and GGT in NASH group 
than non- NASH group (P value < 0.001). 
 
Figure 4: ROC curve to detect a cutoff value of serum aspartate 
transferase (AST) that could predict the development of NASH 
 
Cutoff value for detection of NASH using 
ALT= 50.5 IU/L with sensitivity= 95.5% and 
specificity= 93.8% (Figure 3). Cutoff value for 
detection of NASH using AST= 56 IU/L with 
sensitivity= 90.5% and specificity= 100% (Figure 4). 
Cutoff value for detection of NASH using GGT= 60.5 
IU/L with sensitivity= 86.4% and specificity= 87.5% 
(Figure 5).  
 
Figure 5: ROC curve to detect a cut off value of serum gamma-
glutamyl-transferase (GGT) that could predict the development of 
NASH 
 
 
Discussion 
 
NAFLD includes a spectrum of disorders 
defined essentially by macrovesicular hepatic fat 
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infiltration occurring in people who do not consume 
alcohol in amounts considered harmful to the liver [9]. 
According to the results of the liver biopsy, 
patients were divided into 2 groups the first one 
included patients who were proven to have 
steatohepatitis and the second group included 
patients who do not have steatohepatitis. Although 
the present study cannot differentiate between both 
studied groups as regards sex, we cannot rely on this 
result because of the unequal distribution of sex in the 
study. 
ALT and AST are important markers of liver 
injury. Their levels can be raised in many liver 
diseases. ALT is considered to be more accurate for 
hepatocyte injury and this is mainly attributed to its 
presence in high concentrations in hepatocyte cytosol. 
As regards AST, it has two types, cytosolic and 
mitochondrial and is found in the hepatocytes, 
cardiomyocytes, leukocytes and erythrocytes and 
other tissues [10].  
In the present study, it was found that ALT, 
AST, and GGT were higher in patients with NASH in 
comparison to NAFLD patients, and the difference 
was highly significant. This agrees with Shi and 
colleagues, (2009) [10] who studied patients proven to 
have NAFLD by biopsy and found that ALT and AST 
levels of NASH group were higher than those of non-
NASH group and found also that ALT is a reliable 
indicator of the severity of inflammation. Similarly, 
Fracanzani and colleagues, (2011) (studied patients 
with NAFLD and found that ALT levels were higher in 
steatohepatitis [11].  
In contrast to this, Wong and colleagues. 
(2009) found that patients with ALT less than half the 
upper limit of normal may have the possibility of 
NASH [12]. Also, Oh and colleagues, (2006) found 
that raised ALT above normal values did not 
differentiate between patients who have 
steatohepatitis and patients who do not have 
steatohepatitis by liver biopsy [13]. 
As to AST, Ong and colleagues, (2005) found 
that AST was a reliable predictor of NASH [14]. The 
study done by Pulzi and colleagues, (2011) used a 
cutoff value of 30 IU/L for GGT that has a sensitivity 
70% of and a specificity of 88.6% to distinguish NASH 
from non-NASH groups [15]. Tahan and colleagues, 
(2008) studied biopsy-proven NAFLD patients and 
divided them into normal and high GGT groups and 
found that there were no major differences regarding 
the degree of steatosis and inflammation [16]. 
As to ultrasonography, it is the most widely 
used and less invasive method used for NAFLD 
diagnosis. It can detect steatosis, which appears as 
hyperechogenic parenchyma, termed “bright liver”, 
and “blurring of the vascular margins” [17].  
Regarding liver US, which was done to all 
patients with the same operator prior to biopsy, it was 
found that the prevalent steatotic grade in NASH group 
was grade 3 (37.5%), in comparison to the non-NASH 
group (most of them have grade 1 steatosis (75%). 
This may reflect that the degree of steatosis increases 
when patients develop steatohepatitis. The sensitivity 
of sonar in detecting steatosis compared to liver 
biopsy is 61% in grade 1, 25% of grade 2 and 75% in 
grade 3. 
The results of the current study agree with the 
results of Fracanzani et al, (2011) who found that 
advanced steatosis independently predicts NASH 
[11]. Liver histology is the best diagnostic method for 
grading liver steatosis, inflammation and fibrosis, but it 
is not routinely used in patients with non-progressive 
fatty liver [18]. 
In the present study, the correlation between 
liver ultrasound and liver biopsy was highly significant 
in detecting the degree of hepatic steatosis and 
subsequently the development of NASH. Cutoff value 
for detection of NASH using ALT= 50.5 IU/L with 
sensitivity = 95.5% and specificity = 93.8%. In contrast 
to our results, Verma et al., 2013 found that there is no 
ideal ALT value that can predict NASH and advanced 
fibrosis [19]. The study was done by Somaye et al., 
2011 found that using the cut-off value of 35 IU/L for 
serum ALT level, did not have a major contribution to 
stage NAFLD [20]. 
The present study showed that the cutoff 
value for detection of NASH using AST = 56 IU/L 
(international unit per litre) with sensitivity = 90.5% 
and specificity = 100%, and for GGT = 60.5 IU/L with 
sensitivity = 86.4% and specificity = 87.5%. In regard 
to this, Mikako and Hirofumi, 2012 stated that serum 
GGT value above 96.5 IU/L, predicted the advanced 
stage of fibrosis with 83% sensitivity and 69% 
specificity [21].  
Although the present study tried to highlight 
the important role of US in NAFLD diagnosis and 
also the good correlation between US and biopsy 
results “if done by an experienced operator”, the quite 
novel role of this study is to elucidate also the 
promising role of liver enzymes as surrogate markers 
for NASH development. If we used these parameter 
levels, we can predict the possibility of NASH 
development and so careful follow-up of patients with 
a diet and lifestyle interventions to decrease the 
development of complications such as fibrosis, 
cirrhosis and hepatocellular carcinoma. This 
approach may avoid the need for a liver biopsy 
which may be refused by most patients and so we 
could miss patients who need lifestyle interventions 
and regular follow-up. The combination of all of the 
three parameters may suggest a higher possibility of 
NASH development and so more attention to patient 
follow-up. The importance of this study lies in the 
presentation of an alternative practical tool that could 
help in the diagnosis of NASH without the need for 
invasive tools such as liver biopsy. 
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It is worth to mention that there were some 
limitations in this study such as a discrepancy of a 
number of patients in both groups (NASH patients vs. 
non-NASH patients), and relatively small number of 
the studied patients (it was not easy to persuade 
patients to undergo liver biopsy). 
In the present study, we concluded that liver 
enzymes level can be combined with abdominal sonar 
to predict the presence of NASH as a non-invasive 
method for diagnosis. Larger studies are needed to 
verify the level of liver enzymes that could predict 
accurately NASH development. 
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